Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 4/20 | 0.43 |
| ▸ | PDGFRB known ✓ | P09619 | 9/20 | 0.41 |
| ▸ | KDR known ✓ | P35968 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18574511 | 0.99 | MEN1 (0.47) | MEN1MAPTKMT2AHDAC1PDGFRB | |
| SCHEMBL26725195 | 0.87 | MAPT (0.53) | MEN1MAPTKMT2AHDAC1PDGFRB | |
| SCHEMBL18314056 | 0.85 | MEN1 (0.46) | MEN1MAPTKMT2AHDAC1PDGFRB | |
| SCHEMBL18976114 | 0.84 | HPGD (0.49) | MAPTKMT2AHDAC1KDM4EALDH1A1 | |
| SCHEMBL22824708 | 0.83 | HDAC1 (0.41) | MAPTHDAC1PDGFRBKDRKDM4E | |
| Hydrochloric Acid SCHEMBL20239286 | 0.82 | MEN1 (0.45) | MEN1MAPTKMT2AHDAC1PDGFRB | |
| SCHEMBL18314047 | 0.82 | LEF1 (0.44) | MEN1MAPTKMT2AHDAC1PDGFRB | |
| SCHEMBL26374378 | 0.81 | RAB9A (0.43) | HDAC1KDM4E | |
| SCHEMBL22272502 | 0.81 | HDAC1 (0.52) | MEN1MAPTKMT2AHDAC1PDGFRB | |
| SCHEMBL22824716 | 0.79 | HDAC1 (0.39) | HDAC1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | PHEON THERAPEUTICS LTD (GB) | 2025-01-09 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| EP-4086251-A1 | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY | Femtogenix Limited (GB) | 2022-11-09 | — | — | EP | disclosed |
| CN-114907345-A | Piperidine-benzodiazepine compound having anti-proliferative activity | 福姆通格尼克斯有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-3337795-B1 | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY | FEMTOGENIX LTD (GB) | 2022-06-22 | — | — | EP | disclosed |
| US-20210371413-A1 | POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS | Pheon Therapeutics Ltd. (GB) | 2021-12-02 | — | — | US | disclosed |
| US-20210206763-A1 | Anti-Proliferative Agents | PHEON THERAPEUTICS LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-10975072-B2 | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents | FEMTOGENIX LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-10975074-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | FEMTOGENIX LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20190308970-A1 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED PYRROLO-, INDOLINO- OR TETRAHYDROISOQUINOLINE-BENZODIAZEPINES | PHEON THERAPEUTICS LTD (GB) | 2019-10-10 | — | — | US | disclosed |
| US-10399970-B2 | Pyrridinobenzodiazepine and benzopyrridodiazecine compounds | FEMTOGENIX LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-20180339985-A1 | PDD COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
| US-20180291021-A1 | PDD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-10-11 | — | — | US | disclosed |
| US-20180162855-A1 | PDD AND BPD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371413-A1 | POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS | PBRM1, NFATC1, ACIN1 | HDAC1 349/4885PDGFRB 3084/4885KDR 1773/4885 |
| US-20210206763-A1 | Anti-Proliferative Agents | CCND2, BRD2, DRD2 | HDAC1 262/4885PDGFRB 2035/4885KDR 4258/4885 |
| US-10975074-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, GABRA1, BAK1 | HDAC1 90/4885PDGFRB 652/4885KDR 4246/4885 |
| US-10399970-B2 | Pyrridinobenzodiazepine and benzopyrridodiazecine compounds | DRD1, XDH, DRD2 | HDAC1 1110/4885PDGFRB 3771/4885KDR 3111/4885 |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | HDAC1 147/4885PDGFRB 1891/4885KDR 3268/4885 |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | CCND2, BRD2, CCND3 | HDAC1 270/4885PDGFRB 1585/4885KDR 4059/4885 |
| US-10975072-B2 | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents | PDCD1, CCND1, PDCD6 | HDAC1 658/4885PDGFRB 211/4885KDR 2485/4885 |
| US-20190308970-A1 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED PYRROLO-, INDOLINO- OR TETRAHYDROISOQUINOLINE-BENZODIAZEPINES | GABRA1, GABBR1, GABRA2 | HDAC1 232/4885PDGFRB 684/4885KDR 4306/4885 |
| US-20180291021-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | HDAC1 1205/4885PDGFRB 1988/4885KDR 3473/4885 |
| US-20180162855-A1 | PDD AND BPD COMPOUNDS | DRD1, DRD2, XDH | HDAC1 1198/4885PDGFRB 3538/4885KDR 3243/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | HDAC1 301/4885PDGFRB 214/4885KDR 2855/4885 |
| US-20180339985-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | HDAC1 1085/4885PDGFRB 2265/4885KDR 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.